Diabetes and the Nervous System

Vinik, Aaron I.; Casellini, Carolina; Neumann, Stefanie

doi:10.1007/978-3-030-36694-0_10

Cited by 5 publications

(4 citation statements)

References 452 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pre‐existing impeding factors of SMBG, such as the physical limitations of neuropathy, may not be eliminated in a short period of time after the discharge of patients with an insensitive foot. For patients without sufficient family support, hand dysfunction, which is another symptom of diabetic neuropathy (Vinik et al, 2018), may impede the SMBG performance of patients.…”

Section: Discussionmentioning

confidence: 99%

Factors related to hospital‐to‐home transitional self‐monitoring blood glucose behaviour among patients with diabetes‐related foot ulcer

Chin

Huang

et al. 2021

Int J of Nursing Practice

View full text Add to dashboard Cite

Aims To explore the factors related to hospital‐to‐home transitional self‐monitoring blood glucose behaviour among patients with diabetes‐related foot ulcer. Background The 30‐day readmission rate of patients with diabetes‐related foot ulcer can be reduced when good glycaemic control is achieved. The practice of self‐monitoring blood glucose promotes optimal glycaemic control. Design A comparative descriptive study. Methods In this study, 200 participants, who had been hospitalized due to diabetes‐related foot ulcer, were recruited from August 2017 to July 2018. Before participants were discharged from the hospital, psychosocial factors (family support, threat belief, self‐efficacy and knowledge) and pre‐hospitalization self‐monitoring blood glucose behaviour were collected using a structured questionnaire. Then, after discharge, self‐monitoring blood glucose behaviour delivery was collected again. Results Five variables explained 47% of the variance in the delivery of self‐monitoring of blood glucose at home. The delivery of hospital‐to‐home transitional self‐monitoring blood glucose behaviour was more likely for individuals with higher pre‐discharge self‐efficacy, higher post‐discharge self‐efficacy, more attention to pre‐hospitalization glycaemic status and post‐discharge insulin usage and those without an insensitive foot. Conclusion Self‐monitoring blood‐glucose behaviour should be promoted among post‐discharge patients with diabetes‐related foot ulcer. The modifiable factors identified in this study can be integrated into the discharge plan.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors related to hospital‐to‐home transitional self‐monitoring blood glucose behaviour among patients with diabetes‐related foot ulcer

Chin

Huang

et al. 2021

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…T2DM causes substantial central and peripheral nervous system disturbances [ 17 ]. Neuropathic changes can impair muscle, joint, and cutaneous mechanoreceptors [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

“…Individuals with neuropathy have an increased risk of musculoskeletal disorders and have 15 times increased risk of falls [ 18 ]. As the diabetic nerve is hypoxic, the afferent fibers that transmit kinesthesia and JPS to the higher centers through the spinal cord are significantly affected [ 17 , 19 ]. The hip is one of the most dynamic joints in the body, and hip-joint proprioception is essential for maintaining static and dynamic stability and optimal lower extremity function [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Comparisons and Associations between Hip-Joint Position Sense and Glycosylated Hemoglobin in Elderly Subjects with Type 2 Diabetes Mellitus—A Cross-Sectional Study

Asiri

Reddy

Narapureddy

et al. 2022

IJERPH

View full text Add to dashboard Cite

Hip-joint position sense (JPS) accuracy may be impaired in individuals with type 2 diabetes mellitus (T2DM). An impaired hip JPS can alter postural control and bodily balance. The objectives of this study are to (1) compare the hip JPS between T2DM and asymptomatic and (2) assess the relationship between hip JPS and glycosylated hemoglobin (HbAlc). This comparative cross-sectional study included 117 elderly individuals with T2DM (mean age: 59.82 ± 6.80 y) and 142 who were asymptomatic (mean age: 57.52 ± 6.90 y). The hip JPS was measured using a digital inclinometer. The individuals were repositioned to a target position with their eyes closed, and the magnitudes of matching errors were estimated as reposition errors. The hip JPS was evaluated in the flexion and abduction directions. The magnitude of reposition errors was significantly larger in the T2DM group in the right flexion (p < 0.001), the right abduction (p < 0.001), the left flexion (p < 0.001), and the left abduction (p < 0.001) directions compared to the asymptomatic group. HbA1c values showed a significant positive correlation with JPS in the right-hip flexion (r = 0.43, p < 0.001), the right-hip abduction (r = 0.36, p < 0.001), the left-hip flexion (r = 0.44, p < 0.001), and the left-hip abduction (r = 0.49, p < 0.001) directions. Hip JPS testing may be considered when assessing and formulating treatment strategies for individuals with type 2 diabetes. Future research should focus on how hip JPS can impact balance and falls in individuals with T2DM.

show abstract

“…This can manifest as diabetic peripheral neuropathy (sensory–motor and autonomic) through to cognitive impairment, such as that associated with dementia. 2 Alzheimer's disease (AD) accounts for 60–80% of dementia cases. 3 Similarly to other insulin-sensitive organs, including fat, liver and vascular cells, the central nervous system (CNS) is affected by IR, with an increased risk of neuronal degeneration, neuronal death, and structural and functional impairment of the brain.…”

mentioning

confidence: 99%

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease

Colin¹,

Szczepański²,

Gérard³

et al. 2023

European Endocrinology

View full text Add to dashboard Cite

From an epidemiological and pathophysiological point of view, Alzheimer’s disease (AD) and type 2 diabetes (T2DM) should be considered 'sister' diseases. T2DM significantly increases the risk of developing AD, and the mechanisms of neuronal degeneration themselves worsen peripheral glucose metabolism in multiple ways. The pathophysiological links between the two diseases, particularly cerebral insulin resistance, which causes neuronal degeneration, are so close that AD is sometimes referred to as 'type 3 diabetes'. Although the latest news on the therapeutic front for AD is encouraging, no treatment has been shown to halt disease progression permanently. At best, the treatments slow down the progression; at worst, they are inactive, or cause worrying side effects, preventing their use on a larger scale. Therefore, it appears logical that optimizing the metabolic milieu through preventive or curative measures can also slow down the cerebral degeneration that characterizes AD. Among the different classes of hypoglycaemic drugs, glucagon-like peptide 1 receptor agonists, which are widely used in the treatment of T2DM, were shown to slow down, or even prevent, neuronal degeneration. Data from animal, preclinical, clinical phase II, cohort and large cardiovascular outcomes studies are encouraging. Of course, randomized clinical phase III studies, which are on-going, will be essential to verify this hypothesis. Thus, for once, there is hope for slowing down the neurodegenerative processes associated with diabetes, and that hope is the focus of this review.

show abstract

Diabetes and the Nervous System

Cited by 5 publications

References 452 publications

Factors related to hospital‐to‐home transitional self‐monitoring blood glucose behaviour among patients with diabetes‐related foot ulcer

Factors related to hospital‐to‐home transitional self‐monitoring blood glucose behaviour among patients with diabetes‐related foot ulcer

Comparisons and Associations between Hip-Joint Position Sense and Glycosylated Hemoglobin in Elderly Subjects with Type 2 Diabetes Mellitus—A Cross-Sectional Study

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About